Skip to content Skip to footer

ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)

Menu
Menu

Home

Main menu

Trending

Latest Issue

Articles
Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma
Introduction Renal cell carcinoma (RCC) accounts for 4.2% of adult malignancies and is the 10th leading cause of cancer deaths in the United States.1 In the United States in 2024, more than 81,000 new cases were diagnosed and more than 14,300 died, due…
March 16, 2019
Articles
Practice-Ready Molecular Imaging in Renal Cell Carcinoma
Abstract : BACKGROUND: Renal cell carcinoma (RCC) is the most common kidney malignancy, often associated with poor prognosis due to late-stage diagnosis and metastasis. Recent research has identified PIWI-interacting RNAs (piRNAs) and PIWI-like proteins as potential biomarkers and therapeutic targets in cancer,…
February 20, 2026
Articles
The New Frontier: Advancements in Kidney Cancer Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD Dear colleagues, The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…
February 20, 2026
Articles
Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
February 20, 2026
Articles
The Future of RCC Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…
February 21, 2026
Articles
thank-you
Thank you for subscribing to the Kidney Cancer Journal.  You're now part of a community dedicated to advancing research, treatment, and hope.  We'll be in touch soon
April 1, 2026
2020 2021 2022 2023 2024 2025 Articles
Heading One
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
April 2, 2026

Current Trends

Modifiable risk factors for kidney cancer among adults in India: A systematic review to recommend the most effective preventive measures for kidney cancer in India.
Articles
Nitinkumar Moradiya University Of Sunderland, Harbour Exchange Square, E14 9GE, London, United Kingdom. ABSTRACT Background: Kidney cancer is an emerging public health concern in India, with rising incidence rates and a significant economic burden. While global research has identified common risk…
Molecular and Genomic Biomarkers in Small Renal Masses: A Narrative Review
Articles
biomarkers
This narrative review summarizes the current evidence for molecular and genomic biomarkers in SRM risk stratification and evaluates their potential clinical role.
Heading One
2020 2021 2022 2023 2024 2025 Articles
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…

Explore Our New Articles

Gallery of Articles